Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Update

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 142,800 shares, a growth of 48.8% from the February 28th total of 96,000 shares. Approximately 3.1% of the company’s stock are short sold. Based on an average daily trading volume, of 222,800 shares, the short-interest ratio is presently 0.6 days.

Entero Therapeutics Stock Down 10.2 %

Shares of ENTO stock traded down $0.05 during midday trading on Friday, reaching $0.48. 77,221 shares of the stock were exchanged, compared to its average volume of 382,048. Entero Therapeutics has a 1 year low of $0.19 and a 1 year high of $3.16. The company’s 50 day moving average is $0.52 and its two-hundred day moving average is $0.53.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.